Immutep: Reports data from two separate cancer trials
- Cancer treatment company Immutep (IMM) has released results from two separate clinical trials testing its lead drug, eftilagimod alpha
- The trials are testing the drug, also known as efti, in combination with other conventional cancer treatments
- Today, Immutep revealed some results from early-stage clinical trials using efti.
- Then the first trial, which tested efti with Merk KGaA’s avelumab, recorded a 33 per cent partial response rate
- The second trial, testing efti with Merck & Co’s KEYTRUDA, showed improved response rates in both arms of the trial
- Shareholders seem impressed with today’s results, with Immutep also shares closing 8.11 per cent higher and worth 20 cents each
